Induction of 16α-/2-hydroxyestrone metabolite ratios in MCF-7 cells by pesticides, carcinogens, and antiestrogens does not predict mammary carcinogens

Environmental Health Perspectives

Volumn 106, Issue 4, 1998, Pages 203-206

  McDougal, Andrew ^a   Safe, Stephen ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

16 2 OHE1 ratios; Antiestrogens; Estrogen metabolis; Mammary carcinogens; Pesticides

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHYLENE; 16ALPHA HYDROXYESTRONE; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 3 INDOLEMETHANOL; 4 HYDROXYTAMOXIFEN; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ALITRETINOIN; ANTIESTROGEN; ATRAZINE; BENZO[A]PYRENE; BETA HEXACHLOROCYCLOHEXANE; CARCINOGEN; CHLORDECONE; CHLORPHENOTANE; ESTRADIOL; FULVESTRANT; OXYGENASE; PESTICIDE; TAMOXIFEN; 16 HYDROXYESTRONE; 16-HYDROXYESTRONE; 2 HYDROXYESTRONE; 2-HYDROXYESTRONE; CYTOCHROME P450; ESTRONE DERIVATIVE; STEROID 16ALPHA MONOOXYGENASE; STEROID MONOOXYGENASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; METABOLITE; PREDICTION; PRIORITY JOURNAL; RADIOMETRY; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DRUG SCREENING; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; METABOLISM; PATHOLOGY; PREDICTION AND FORECASTING;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; HYDROXYESTRONES; MAMMARY NEOPLASMS, EXPERIMENTAL; PESTICIDES; PREDICTIVE VALUE OF TESTS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TUMOR CELLS, CULTURED;

EID: 0031595971     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.98106203     Document Type: Article

References (32)

1. Hulka BS, Liu ET, Lininger RA. Steroid hormones and risk of breast cancer, Cancer 74:1111-1124 (1994).
2. Hulka BS. Epidemiologic analysis of breast and gynecologic cancers. In: Etiology of Breast and Gynecological Cancers (Aldaz M, Gould MN, McLachlan J, Slaga TJ, eds). New York:Wiley-Liss, Inc. 1997:17-29.
3. Russo J, Russo IH. Toward a unified concept of mammary carcinogenesis. In: Etiology of Breast and Gynecological Cancers (Aldaz M, Gould MN, McLachlan J, Slaga TJ, eds). New York:Wiley-Liss, Inc. 1997;1-16.
4. Russo J, Russo IH. Experimentally induced mammary tumors in rats. Breast Cancer Res Treat 39:7-20 (1996).
5. Liehr JG. Hormone-associated cancer; mechanistic similarities between human breast cancer and estrogen-induced kidney carcinogenesis in hamsters. Environ Health Perspect 105(suppl 3):565-569 (1997).
6. Li JJ, Li SA. Estrogen carcinogenesis in hamster tissues: a critical review. Endocr Rev 11:524-531 (1990).
7. Liehr JG. Genotoxic effects of estrogens. Mutat Res 238:269-276 (1990).
8. Bradlow HL, Davis DL, Lin G, Sepkovic D, Tiwari R. Effects of pesticides on the ratio of 16α/2-hydroxyestrone: a biologic marker of breast cancer risk. Environ Health Perspect 103(suppl 7):147-150 (1995).
9. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-Hydroxyestrone: the 'good' estrogen. J Endocrinol 150:S259-S263 (1996).
10. Telang NT, Katdare M, Bradlow HL, Osborne MP, Estradiol metabolism: an endocrine biomarker for modulation of human mammary carcinogenesis. Environ Health Perspect 105(suppl 3):559-564 (1997).
11. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J. Estradiol 16α-hydroxylation in the mouse correlate with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci USA 82:6295-6299 (1985).
12. Telang NT, Bradlow HL, Osborne MP. Molecular and endocrine biomarkers in non-involved breast: relevance to cancer chemoprevention. J Cell Biochem Suppl 16G:161-169 (1992).
13. Telang NT, Suto A, Wong GY, Osborne MO, Bradlow HL. Induction by estrogen metabolite 16α-hydroxye-strone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84:634-638 (1992).
14. Osborne MP, Bradlow HL, Wong GY, Telang NT. Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst 85:1917-1920 (1993).
15. Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, Fishman J. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 79:3047-3051 (1982).
16. Tiwari RK, Guo L, Bradlow HL, Telang NT, Osborne MP. Selective responsiveness of breast cancer cells to indole-3-carbinol, a chemopreventative agent. J Natl Cancer Inst 86:126-131 (1994).
17. Chen I, Safe S, Bjeldanes L. Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem Pharmacol 51:1069-1076 (1996).
18. Safe SH, Chen I, Porter W. Dietary indoles with antiestrogenic activity in common vegetables and their implications. In: Estrogens. Progestins and Their Antagonists (Pavlik E, ed). Boston, MA:Birkhouser, 1996:73-97.
19. Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Therap 45:241-298 (1990).
20. McDougal A, Wilson C, Safe S. Induction of estradiol 2-hydroxylass activity in MCF-7 human breast cancer cells by pesticides and carcinogens. Environ Toxicol Pharmacol 3:195-199 (1997).
21. Villalobos M, Olea N, Brotons JA, Olea-Serrano MF, Ruiz de Almodovar JM, Pedraza V. The E-screen assay: a comparison of different MCF7 cell stocks. Environ Health Perspect 103:844-850 (1995).
22. Klotz DM, Castles CG, Spriggs LL, Hill SM. Differential expression of wild-type and variant ER mRNAs by stocks of MCF-7 breast cancer cells may account for differences in estrogen responsiveness. Biochem Biophys Res Commun 210:609-615 (1995).
23. Gierthy JF, Lincoln DW, Kampcik SJ, Dickerman HW, Bradlow HL, Niwa T, Swaneck GE. Enhancement of 2-and 16α-estradiol hydroxylation in MCF-7 human breast cancer cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem Biophys Res Commun 157:515-520 (1988).
24. Spink DC, Lincoln DW, Dickerman HW, Gierthy JF. 2,3,7,8-Tetrachlorodibenzo-p-dioxin causes an extensive alteration of 17β-estradiol metabolism in human breast cancer cells. Proc Natl Acad Sci USA 87:6917-6921 (1990).
25. Spink DC, Eugster H, Lincoln DW II, Schuetz JD, Schuetz EG, Johnson JA, Kaminsky LS, Gierthy JF. 17β-Estradiol hydroxylation catalyzed by human cytochrome P4501A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch Biochem Biophys 293: 342-348 (1992).
26. Spink DC, Johnson JA, Connor SP, Aldous KM, Gierthy JF. Stimulation of 17β-estradiol metabolism in MCF-7 cells by bromochloro- and chloromethyl-substituted dibenzo-p-dioxins and dibenzofurans: correlations with antiestrogenic activity. J Toxicol Environ Health 41:451-466 (1994).
27. Graham MJ, Lucier GW, Linko P, Maronpot RR, Goldstein JA. Increases in cytochrome P-450 mediated 17β-estradiol 2-hydroxylase activity in rat liver microsomes after both acute administration and subchronic administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin in a two-stage hepatocarcinogenesis model. Carcinogenesis 9:1935-1941 (1988).
28. Ryan DE, Thomas PE, Levin W. Purification and characterization of a minor form of hepatic microsomal cytochrome P-450 from rats treated with polychlorinated biphenyls. Arch Biochem Biophys 216:272-288 (1982).
29. Dannan GA, Porubeck DJ, Nelson SD, Waxman DJ, Guengerich FP. 17β-Estradiol 2- and 4-hydroxylation catalyzed by rat hepatic cytochrome P-450: roles of individual forms, inductive effects, developmental patterns, and alterations by gonadectomy. Endocrinology 118:1952-1960 (1986).
30. Moore M, Wang X, Lu Y-F, Wormke M, Craig A, Gerlach J, Burghardt R, Safe S, Benzo[a]pyrene resistant (BaP) human breast cancer cells: a unique aryl hydrocarbon (Ah)-nonresponsive clone. J Biol Chem 269:11751-11759 (1994).
31. Harris M, Piskorske-Pliszczynska J, Zacharawski T, Romkes M, Safe S. Structure-dependent induction of aryl hydrocarbon hydroxylase in human breast cancer cell lines and characterization of the Ah receptor. Cancer Res 49:4531-4535 (1989).
32. Wakeling AE. The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 25:1-9 (1993).